JP5934107B2 - コア安定化マイクロカプセル、それらの調製法及びそれらの使用 - Google Patents
コア安定化マイクロカプセル、それらの調製法及びそれらの使用 Download PDFInfo
- Publication number
- JP5934107B2 JP5934107B2 JP2012546557A JP2012546557A JP5934107B2 JP 5934107 B2 JP5934107 B2 JP 5934107B2 JP 2012546557 A JP2012546557 A JP 2012546557A JP 2012546557 A JP2012546557 A JP 2012546557A JP 5934107 B2 JP5934107 B2 JP 5934107B2
- Authority
- JP
- Japan
- Prior art keywords
- metal oxide
- microcapsules
- aqueous phase
- core
- microcapsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003094 microcapsule Substances 0.000 title claims description 73
- 238000000034 method Methods 0.000 title claims description 61
- 238000002360 preparation method Methods 0.000 title claims description 30
- 239000000203 mixture Substances 0.000 claims description 99
- 239000008346 aqueous phase Substances 0.000 claims description 49
- 229910044991 metal oxide Inorganic materials 0.000 claims description 48
- 150000004706 metal oxides Chemical class 0.000 claims description 47
- 239000012071 phase Substances 0.000 claims description 47
- 239000003921 oil Substances 0.000 claims description 43
- 239000013543 active substance Substances 0.000 claims description 24
- 239000012782 phase change material Substances 0.000 claims description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 239000002105 nanoparticle Substances 0.000 claims description 22
- -1 metalloid alkoxide Chemical class 0.000 claims description 19
- 239000000178 monomer Substances 0.000 claims description 17
- 229910052751 metal Inorganic materials 0.000 claims description 14
- 239000002184 metal Substances 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 10
- 239000000839 emulsion Substances 0.000 claims description 10
- 229910052752 metalloid Inorganic materials 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 238000004945 emulsification Methods 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 201000004700 rosacea Diseases 0.000 claims description 6
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 241001303601 Rosacea Species 0.000 claims description 5
- 206010039792 Seborrhoea Diseases 0.000 claims description 5
- 206010000496 acne Diseases 0.000 claims description 5
- 239000002537 cosmetic Substances 0.000 claims description 5
- 238000004132 cross linking Methods 0.000 claims description 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 5
- 206010012442 Dermatitis contact Diseases 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 208000010247 contact dermatitis Diseases 0.000 claims description 4
- 239000007764 o/w emulsion Substances 0.000 claims description 4
- 239000012188 paraffin wax Substances 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 238000011200 topical administration Methods 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 3
- 239000003905 agrochemical Substances 0.000 claims description 3
- 230000001804 emulsifying effect Effects 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- 229920000867 polyelectrolyte Polymers 0.000 claims description 3
- 150000002191 fatty alcohols Chemical class 0.000 claims 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 59
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical group C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 44
- 235000019400 benzoyl peroxide Nutrition 0.000 description 44
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- 239000011162 core material Substances 0.000 description 35
- 239000000725 suspension Substances 0.000 description 31
- 238000002844 melting Methods 0.000 description 30
- 230000008018 melting Effects 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 23
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 21
- 238000009472 formulation Methods 0.000 description 20
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 18
- 229940032094 squalane Drugs 0.000 description 18
- 239000004372 Polyvinyl alcohol Substances 0.000 description 16
- 239000007788 liquid Substances 0.000 description 16
- 229920002451 polyvinyl alcohol Polymers 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 15
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical group [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 15
- 238000005538 encapsulation Methods 0.000 description 14
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical group [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 12
- 235000013871 bee wax Nutrition 0.000 description 12
- 239000012166 beeswax Substances 0.000 description 12
- 239000012703 sol-gel precursor Substances 0.000 description 12
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 11
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 10
- 239000004094 surface-active agent Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 9
- 239000001993 wax Substances 0.000 description 8
- 239000004115 Sodium Silicate Substances 0.000 description 7
- 239000002270 dispersing agent Substances 0.000 description 7
- 239000004200 microcrystalline wax Substances 0.000 description 7
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical group [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 7
- 229910052911 sodium silicate Inorganic materials 0.000 description 7
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 229910021538 borax Inorganic materials 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 238000010008 shearing Methods 0.000 description 6
- 235000010339 sodium tetraborate Nutrition 0.000 description 6
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 6
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical group CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 5
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 5
- 239000003093 cationic surfactant Substances 0.000 description 5
- 235000010413 sodium alginate Nutrition 0.000 description 5
- 239000000661 sodium alginate Substances 0.000 description 5
- 229940005550 sodium alginate Drugs 0.000 description 5
- 229910001388 sodium aluminate Inorganic materials 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- ANBBXQWFNXMHLD-UHFFFAOYSA-N aluminum;sodium;oxygen(2-) Chemical compound [O-2].[O-2].[Na+].[Al+3] ANBBXQWFNXMHLD-UHFFFAOYSA-N 0.000 description 4
- 229940085237 carbomer-980 Drugs 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 235000019808 microcrystalline wax Nutrition 0.000 description 4
- 229910052710 silicon Inorganic materials 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 3
- 150000004703 alkoxides Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 239000011258 core-shell material Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000003760 magnetic stirring Methods 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 229960001727 tretinoin Drugs 0.000 description 3
- ASKIVFGGGGIGKH-UHFFFAOYSA-N 2,3-dihydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)CO ASKIVFGGGGIGKH-UHFFFAOYSA-N 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920000289 Polyquaternium Polymers 0.000 description 2
- 229920003081 Povidone K 30 Polymers 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
- LWZFANDGMFTDAV-WYDSMHRWSA-N [2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-WYDSMHRWSA-N 0.000 description 2
- 229920006322 acrylamide copolymer Polymers 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 239000000058 anti acne agent Substances 0.000 description 2
- 229940124340 antiacne agent Drugs 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 229940075509 carbomer 1342 Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 229920001600 hydrophobic polymer Polymers 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012170 montan wax Substances 0.000 description 2
- UTOPWMOLSKOLTQ-UHFFFAOYSA-N octacosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O UTOPWMOLSKOLTQ-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000011368 organic material Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229920000371 poly(diallyldimethylammonium chloride) polymer Polymers 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- IUMSDRXLFWAGNT-UHFFFAOYSA-N Dodecamethylcyclohexasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 IUMSDRXLFWAGNT-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004111 Potassium silicate Substances 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- NJSSICCENMLTKO-HRCBOCMUSA-N [(1r,2s,4r,5r)-3-hydroxy-4-(4-methylphenyl)sulfonyloxy-6,8-dioxabicyclo[3.2.1]octan-2-yl] 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)O[C@H]1C(O)[C@@H](OS(=O)(=O)C=2C=CC(C)=CC=2)[C@@H]2OC[C@H]1O2 NJSSICCENMLTKO-HRCBOCMUSA-N 0.000 description 1
- 229960002916 adapalene Drugs 0.000 description 1
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- KVLCHQHEQROXGN-UHFFFAOYSA-N aluminium(1+) Chemical compound [Al+] KVLCHQHEQROXGN-UHFFFAOYSA-N 0.000 description 1
- 229940007076 aluminum cation Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000000656 azaniumyl group Chemical group [H][N+]([H])([H])[*] 0.000 description 1
- 239000012179 bayberry wax Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229910010293 ceramic material Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012174 chinese wax Substances 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229940000033 dermatological agent Drugs 0.000 description 1
- 239000003241 dermatological agent Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- JJQZDUKDJDQPMQ-UHFFFAOYSA-N dimethoxy(dimethyl)silane Chemical group CO[Si](C)(C)OC JJQZDUKDJDQPMQ-UHFFFAOYSA-N 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- GQOKIYDTHHZSCJ-UHFFFAOYSA-M dimethyl-bis(prop-2-enyl)azanium;chloride Chemical compound [Cl-].C=CC[N+](C)(C)CC=C GQOKIYDTHHZSCJ-UHFFFAOYSA-M 0.000 description 1
- NJLLQSBAHIKGKF-UHFFFAOYSA-N dipotassium dioxido(oxo)titanium Chemical compound [K+].[K+].[O-][Ti]([O-])=O NJLLQSBAHIKGKF-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000010687 lubricating oil Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- BFXIKLCIZHOAAZ-UHFFFAOYSA-N methyltrimethoxysilane Chemical group CO[Si](C)(OC)OC BFXIKLCIZHOAAZ-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- NNHHDJVEYQHLHG-UHFFFAOYSA-N potassium silicate Chemical compound [K+].[K+].[O-][Si]([O-])=O NNHHDJVEYQHLHG-UHFFFAOYSA-N 0.000 description 1
- 229910052913 potassium silicate Inorganic materials 0.000 description 1
- 235000019353 potassium silicate Nutrition 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 239000004170 rice bran wax Substances 0.000 description 1
- 235000019384 rice bran wax Nutrition 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 125000005372 silanol group Chemical group 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- GROMGGTZECPEKN-UHFFFAOYSA-N sodium metatitanate Chemical compound [Na+].[Na+].[O-][Ti](=O)O[Ti](=O)O[Ti]([O-])=O GROMGGTZECPEKN-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- IJCWFDPJFXGQBN-BIFNRIDTSA-N sorbitan tristearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@@H](O)[C@@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-BIFNRIDTSA-N 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- LFQCEHFDDXELDD-UHFFFAOYSA-N tetramethyl orthosilicate Chemical group CO[Si](OC)(OC)OC LFQCEHFDDXELDD-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/11—Encapsulated compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/25—Silicon; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/26—Aluminium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/38—Percompounds, e.g. peracids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/06—Making microcapsules or microballoons by phase separation
- B01J13/14—Polymerisation; cross-linking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29159409P | 2009-12-31 | 2009-12-31 | |
| US61/291,594 | 2009-12-31 | ||
| PCT/IL2010/001092 WO2011080741A2 (en) | 2009-12-31 | 2010-12-30 | Core stabilized microcapsules, method of their preparation and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013516404A JP2013516404A (ja) | 2013-05-13 |
| JP2013516404A5 JP2013516404A5 (enExample) | 2014-01-16 |
| JP5934107B2 true JP5934107B2 (ja) | 2016-06-15 |
Family
ID=44226918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012546557A Expired - Fee Related JP5934107B2 (ja) | 2009-12-31 | 2010-12-30 | コア安定化マイクロカプセル、それらの調製法及びそれらの使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10512796B2 (enExample) |
| EP (1) | EP2467132B1 (enExample) |
| JP (1) | JP5934107B2 (enExample) |
| KR (1) | KR20130008002A (enExample) |
| CN (1) | CN102596186B (enExample) |
| AU (1) | AU2010337830B2 (enExample) |
| BR (1) | BR112012012023A2 (enExample) |
| CA (1) | CA2773544C (enExample) |
| EA (1) | EA201200347A1 (enExample) |
| ES (1) | ES2611499T3 (enExample) |
| MX (1) | MX344128B (enExample) |
| WO (1) | WO2011080741A2 (enExample) |
| ZA (1) | ZA201203582B (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2545776A3 (en) | 2007-02-01 | 2014-12-24 | Sol-Gel Technologies Ltd. | Method for preparing particles comprising metal oxide coating and particles with metal oxide coating |
| JP2011529392A (ja) | 2008-07-31 | 2011-12-08 | ゾル−ゲル テクノロジー リミテッド | 活性成分および金属酸化物シェルを含むマイクロカプセル、その製造方法およびその使用 |
| US10653899B2 (en) | 2009-12-31 | 2020-05-19 | Sol-Gel Technologies Ltd. | Core stabilized microcapsules, method of their preparation and uses thereof |
| CN102596186B (zh) | 2009-12-31 | 2017-08-11 | 索尔-格尔科技有限公司 | 芯稳定的微胶囊、它们的制备方法以及它们的用途 |
| US11071878B2 (en) | 2009-12-31 | 2021-07-27 | Sol-Gel Technologies Ltd. | Core stabilized microcapsules, method of their preparation and uses thereof |
| CA2834681C (en) | 2011-06-29 | 2019-03-12 | Sol-Gel Technologies Ltd. | Stabilized topical formulations containing core-shell microcapsules |
| BR112014012444B1 (pt) | 2011-11-23 | 2021-12-14 | Therapeuticsmd, Inc | Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher |
| EP2822743A1 (en) * | 2012-04-18 | 2015-01-14 | Rohm and Haas Company | Wax-biocide wood treatment |
| US10806697B2 (en) * | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| CN102726383B (zh) * | 2012-07-05 | 2015-03-18 | 常州美胜生物材料有限公司 | 一种缓释型害虫引诱剂微胶囊及其制备方法 |
| FI126168B (en) | 2012-09-18 | 2016-07-29 | Novaldmedical Ltd Oy | A method for coating pharmaceutical substrates |
| CA2889199C (en) * | 2012-11-27 | 2020-05-19 | Sol-Gel Technologies Ltd. | Compositions for the treatment of rosacea |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| CN104624125B (zh) * | 2013-11-11 | 2018-03-02 | 中国人民银行印制科学技术研究所 | 一种光致变色双壳微胶囊及其制备方法和应用 |
| CN103908912A (zh) * | 2014-03-13 | 2014-07-09 | 安徽明讯新材料科技有限公司 | 一种相变恒温配胶容器 |
| US9480960B2 (en) * | 2014-12-01 | 2016-11-01 | National Chung Shan Institute Of Science And Technology | Process for preparing phase change microcapsule having thermally conductive shell |
| BR112017023472B1 (pt) * | 2015-05-13 | 2021-10-13 | Unilever Ip Holdings B.V | Partícula de fornecimento de agente benéfico, composição e processo de produção de partículas |
| CA2996022C (en) * | 2015-08-20 | 2021-01-05 | Sol-Gel Technologies Ltd. | Compositions for topical application comprising benzoyl peroxide and adapalene |
| KR101779846B1 (ko) | 2015-08-31 | 2017-10-10 | 주식회사 티케이케미칼 | 나노다공성을 갖는 서방성 미분말과 그 제조방법 |
| CN105754554B (zh) * | 2016-02-02 | 2019-02-19 | 中南林业科技大学 | 一种含纳米TiO2的纤维素基低温相变储能微胶囊及其制备方法 |
| EP3419659A1 (en) | 2016-02-23 | 2019-01-02 | The Regents of the University of Colorado, A Body Corporate | Compositions and methods for making and using thermostable immunogenic formulations with increased compatibility of use as vaccines against one or more pathogens |
| CA3016436C (en) * | 2016-03-04 | 2025-05-27 | Arkema Inc. | PEROXIDE ENCAPSULATION FOR SKIN APPLICATIONS |
| CN105797659B (zh) * | 2016-04-08 | 2018-12-14 | 东南大学 | 一种二氧化硅壳聚糖双壳储热微胶囊的制备方法 |
| EP3651756B1 (en) * | 2017-07-12 | 2025-09-03 | Sol-Gel Technologies Ltd. | Compositions comprising encapsulated tretinoin |
| WO2019012536A1 (en) | 2017-07-12 | 2019-01-17 | Sol-Gel Technologies Ltd. | METHODS AND COMPOSITIONS FOR TREATING ACNEA |
| CN107213806B (zh) * | 2017-07-13 | 2018-03-06 | 广州达济医学科技有限公司 | 一种用于滤除白细胞的滤膜及其制备方法 |
| US11643584B2 (en) * | 2017-11-16 | 2023-05-09 | Georgia Tech Research Corporation | Incorporation of microencapsulated phase change materials into wet-spin dry jet polymeric fibers |
| KR102496427B1 (ko) | 2018-01-16 | 2023-02-06 | 어플라이드 머티어리얼스, 인코포레이티드 | 금속 산화물로 캡슐화된 약물 조성물들 및 그의 제조 방법들 |
| CN109338135B (zh) * | 2018-10-11 | 2020-07-14 | 西北工业大学 | 一种核壳结构Al@Ti-Al2O3相变蓄热复合材料及制备方法 |
| RU2701030C1 (ru) * | 2018-12-29 | 2019-09-24 | Федеральное государственное бюджетное учреждение науки Институт элементоорганических соединений им. А.Н. Несмеянова Российской академии наук (ИНЭОС РАН) | Способ получения полых кремнеземных нанокапсул |
| US10933046B2 (en) | 2019-02-19 | 2021-03-02 | Sol-Gel Technologies, Ltd. | Method for treatment of rosacea in patients aged 65 years and older |
| JP7395611B2 (ja) | 2019-04-17 | 2023-12-11 | ザ プロクター アンド ギャンブル カンパニー | カプセル |
| EP3956054A1 (en) | 2019-04-17 | 2022-02-23 | The Procter & Gamble Company | Methods of making capsules |
| MX2021012435A (es) | 2019-04-17 | 2021-11-17 | Procter & Gamble | Capsulas. |
| WO2021006615A1 (ko) * | 2019-07-09 | 2021-01-14 | 주식회사 엘지생활건강 | 화장품용 캡슐 |
| EP4082624B1 (en) * | 2019-12-27 | 2024-10-23 | Kao Corporation | Method for preparing microcapsule |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
| WO2021234716A1 (en) | 2020-05-22 | 2021-11-25 | Sol-Gel Technologies Ltd. | Stabilized microcapsules, method of their preparation and uses thereof |
| TWI870622B (zh) | 2020-10-02 | 2025-01-21 | 美商應用材料股份有限公司 | 製備氧化矽塗佈藥品的低溫處理 |
| JP2023543576A (ja) | 2020-10-16 | 2023-10-17 | ザ プロクター アンド ギャンブル カンパニー | コア／シェルカプセルを含有する水溶性単位用量物品 |
| MX2023004226A (es) | 2020-10-16 | 2023-04-21 | Procter & Gamble | Composiciones antitranspirantes y desodorantes que comprenden capsulas. |
| US12458942B2 (en) | 2020-10-16 | 2025-11-04 | The Procter & Gamble Company | Capsules |
| JP7688120B2 (ja) | 2020-10-16 | 2025-06-03 | ザ プロクター アンド ギャンブル カンパニー | 洗濯物ケア添加剤粒子 |
| MX2023004227A (es) | 2020-10-16 | 2023-04-21 | Procter & Gamble | Composiciones liquidas para el cuidado de telas que comprenden capsulas. |
| CN112143476B (zh) * | 2020-10-21 | 2022-03-04 | 南京工业大学 | 一种采用微流场反应技术制备纳米包覆驱油剂的方法及装置 |
| EP4268949A4 (en) * | 2020-12-28 | 2024-11-13 | Kao Corporation | Microcapsule |
| CN116710545A (zh) * | 2020-12-28 | 2023-09-05 | 花王株式会社 | 二氧化硅微胶囊的制造方法 |
| WO2023056304A1 (en) | 2021-09-30 | 2023-04-06 | Applied Materials, Inc. | Low temperature silicon oxide coating for pharmaceutical applications |
| CN116919939A (zh) * | 2022-04-02 | 2023-10-24 | 南京毓浠医药技术有限公司 | 一种维a酸和过氧化苯甲酰组合物及其制备方法和用途 |
| US12275885B2 (en) * | 2022-07-13 | 2025-04-15 | King Fahd University Of Petroleum And Minerals | Doped phase change material and method of preparation thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3906108A (en) | 1973-10-12 | 1975-09-16 | Johnson & Johnson | Stabilized tretinoin cream emulsion |
| GB9021061D0 (en) | 1990-09-27 | 1990-11-07 | Unilever Plc | Encapsulating method and products containing encapsulated material |
| CA2156931C (en) | 1993-02-26 | 2001-12-11 | Julius R. Zecchino | Titanium dioxide dispersions, cosmetic compositions and methods for using the same |
| US5401517A (en) | 1993-11-15 | 1995-03-28 | Elizabeth Arden Company, Division Of Conopco, Inc. | Cosmetic method for treatment of skin |
| US5720949A (en) | 1996-05-06 | 1998-02-24 | Bristol-Myers Squibb Company | Foamable cosmetic mask product |
| US5891476A (en) | 1997-12-22 | 1999-04-06 | Reo; Joe P. | Tastemasked pharmaceutical system |
| ES2216360T3 (es) | 1998-02-06 | 2004-10-16 | Seiwa Kasei Co., Ltd. | Microcapsula con pared particular y su procedimiento de fabricacion. |
| US6099894A (en) | 1998-07-27 | 2000-08-08 | Frisby Technologies, Inc. | Gel-coated microcapsules |
| AU5382599A (en) | 1998-08-13 | 2000-03-06 | Sol-Gel Technologies Ltd. | Method for the preparation of oxide microcapsules loaded with functional molecules and the products obtained thereof |
| US6468509B2 (en) | 1998-12-18 | 2002-10-22 | Sol-Gel Technologies Ltd. | Sunscreen composition containing sol-gel microcapsules |
| US6238650B1 (en) | 1999-05-26 | 2001-05-29 | Sol-Gel Technologies Ltd. | Sunscreen composition containing sol-gel microcapsules |
| ES2283300T3 (es) | 1999-05-25 | 2007-11-01 | Sol-Gel Technologies Ltd. | Un procedimiento para obtener composiciones de filtros solares fotoestables. |
| US7758888B2 (en) | 2000-04-21 | 2010-07-20 | Sol-Gel Technologies Ltd. | Composition exhibiting enhanced formulation stability and delivery of topical active ingredients |
| BR0110600A (pt) * | 2000-04-21 | 2003-04-15 | Sol Gel Technologies Ltd | Composição terapêutica ou cosmética para aplicação tópica e processo para preparação de micro-cápsulas de sol-gel |
| WO2004081222A2 (en) | 2003-03-14 | 2004-09-23 | Sol-Gel Technologies Ltd. | Agent-encapsulating micro- and nanoparticles, methods for preparation of same and products containing same |
| CN100453162C (zh) | 2003-07-31 | 2009-01-21 | 索尔-格尔科技有限公司 | 装载有活性成分的微胶囊及其制备方法 |
| DE102004017221A1 (de) | 2004-04-05 | 2005-10-20 | Cognis Ip Man Gmbh | O/W-Gel-Zusammensetzungen mit Estern des Pentaerythrits oder dessen Oligomeren |
| US20080249192A1 (en) | 2004-04-05 | 2008-10-09 | Caroline Goget | Wax Mixture Based on Partial Glycerides and Pentaerythriol Esters |
| EP1919606A2 (en) * | 2005-08-02 | 2008-05-14 | Sol-Gel Technologies Ltd. | Metal oxide coating of water insoluble ingredients |
| US9107844B2 (en) | 2006-02-03 | 2015-08-18 | Stiefel Laboratories Inc. | Topical skin treating compositions |
| BRPI0720068A2 (pt) * | 2006-12-12 | 2013-12-24 | Sol Gel Technologies Ltd | Processo para preparar nanocápsulas, produto, nanocápsulas e composição |
| US20100047357A1 (en) | 2007-02-01 | 2010-02-25 | Sol-Gel Technologies Ltd. | Compositions for topical application comprising a peroxide and retinoid |
| KR100837558B1 (ko) | 2007-04-30 | 2008-06-12 | (주)아모레퍼시픽 | 이중으로 안정된 세라마이드 나노 캡슐 포함 에멀젼조성물, 그의 제조방법 및 이를 이용한 피부 화장료 조성물 |
| US8357318B2 (en) | 2007-05-08 | 2013-01-22 | Givaudan S.A. | Wax encapsulation |
| JP2011529392A (ja) | 2008-07-31 | 2011-12-08 | ゾル−ゲル テクノロジー リミテッド | 活性成分および金属酸化物シェルを含むマイクロカプセル、その製造方法およびその使用 |
| CN102596186B (zh) | 2009-12-31 | 2017-08-11 | 索尔-格尔科技有限公司 | 芯稳定的微胶囊、它们的制备方法以及它们的用途 |
-
2010
- 2010-12-30 CN CN201080042302.5A patent/CN102596186B/zh active Active
- 2010-12-30 CA CA2773544A patent/CA2773544C/en active Active
- 2010-12-30 EA EA201200347A patent/EA201200347A1/ru unknown
- 2010-12-30 BR BR112012012023A patent/BR112012012023A2/pt not_active IP Right Cessation
- 2010-12-30 EP EP10805340.6A patent/EP2467132B1/en active Active
- 2010-12-30 KR KR1020127009212A patent/KR20130008002A/ko not_active Withdrawn
- 2010-12-30 WO PCT/IL2010/001092 patent/WO2011080741A2/en not_active Ceased
- 2010-12-30 JP JP2012546557A patent/JP5934107B2/ja not_active Expired - Fee Related
- 2010-12-30 AU AU2010337830A patent/AU2010337830B2/en not_active Ceased
- 2010-12-30 MX MX2012006636A patent/MX344128B/es active IP Right Grant
- 2010-12-30 US US13/500,937 patent/US10512796B2/en active Active
- 2010-12-30 ES ES10805340.6T patent/ES2611499T3/es active Active
-
2012
- 2012-05-16 ZA ZA2012/03582A patent/ZA201203582B/en unknown
-
2017
- 2017-12-07 US US15/834,805 patent/US20180117369A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2012006636A (es) | 2012-07-10 |
| CN102596186A (zh) | 2012-07-18 |
| WO2011080741A2 (en) | 2011-07-07 |
| CA2773544C (en) | 2019-02-12 |
| EA201200347A1 (ru) | 2012-07-30 |
| US10512796B2 (en) | 2019-12-24 |
| CN102596186B (zh) | 2017-08-11 |
| AU2010337830B2 (en) | 2013-10-03 |
| EP2467132A2 (en) | 2012-06-27 |
| EP2467132B1 (en) | 2016-10-19 |
| MX344128B (es) | 2016-12-06 |
| ES2611499T3 (es) | 2017-05-09 |
| CA2773544A1 (en) | 2011-07-07 |
| KR20130008002A (ko) | 2013-01-21 |
| AU2010337830A1 (en) | 2012-03-22 |
| US20180117369A1 (en) | 2018-05-03 |
| US20120202695A1 (en) | 2012-08-09 |
| JP2013516404A (ja) | 2013-05-13 |
| WO2011080741A3 (en) | 2011-10-13 |
| ZA201203582B (en) | 2013-01-30 |
| BR112012012023A2 (pt) | 2016-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5934107B2 (ja) | コア安定化マイクロカプセル、それらの調製法及びそれらの使用 | |
| US12070629B2 (en) | Core stabilized microcapsules, method of their preparation and uses thereof | |
| US10653899B2 (en) | Core stabilized microcapsules, method of their preparation and uses thereof | |
| JP6033859B2 (ja) | コア−シェルマイクロカプセル含有安定化局所製剤 | |
| JP6788066B2 (ja) | 過酸化ベンゾイルおよびアダパレンを含む局所投与用組成物 | |
| US9763862B2 (en) | Multicompartmentalized material for the thermostimulated delivery of substances of interest, preparation method thereof and uses of the same | |
| ES3040940T3 (en) | Compositions comprising encapsulated tretinoin | |
| HK1169943B (en) | Core stabilized microcapsules, method of their preparation and uses thereof | |
| HK1169943A (en) | Core stabilized microcapsules, method of their preparation and uses thereof | |
| JP6811213B2 (ja) | 酒さの治療のための組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131119 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131119 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140812 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140814 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141111 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141118 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141212 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150203 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150427 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20150428 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150825 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151125 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151225 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160203 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160217 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160413 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160506 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5934107 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |